StockVS

Haleon plc (HLN) 株式分析

ヘルスケア

Haleon plc

$9.24

$-0.05 (-0.54%)

最終更新日: 2026年5月26日

株価推移

分析

企業概要

Haleon plc is a global entity dedicated to the research, development, manufacturing, and commercialization of an extensive portfolio of consumer healthcare products, including oral care items such as toothpastes and mouthwashes, distributed across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. This business operates within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, positioning it as a key player in the non-prescription pharmaceutical landscape. The company demonstrates substantial scale with a market capitalization of $44.61B, annual revenue of $11.03B, and a workforce comprising 24,535 employees. These valuation and revenue figures indicate that Haleon plc commands a significant market presence, reflecting its status as a major multinational corporation capable of sustaining operations and generating substantial cash flows across diverse geographic regions.

財務健全性

The company reported a trailing twelve-month revenue of $11.03B and net income of $1.67B, with EBITDA reaching $2.74B, highlighting a substantial difference between top-line sales and bottom-line profits that reveals a significant cost structure involving operating expenses, taxes, and interest costs. Free cash flow stood at $1.40B, a metric that underscores the company's financial flexibility to fund capital expenditures, service its debt obligations, and potentially pursue strategic acquisitions without immediate reliance on external financing. The gross margin is 64.8%, indicating strong pricing power and efficient production processes for consumer goods, while the operating margin of 23.2% and profit margin of 15.1% further demonstrate the entity's ability to control overhead and generate profitability after all expenses. Regarding leverage, total cash holdings of $1.35B are lower than total debt of $8.63B, resulting in a debt-to-equity ratio of 52.37, which suggests the balance sheet is leveraged rather than conservative. The current ratio of 0.92 indicates that current assets are slightly below current liabilities, suggesting a need for careful management of short-term liquidity to meet obligations as they come due. Return on equity is 10.3% and return on assets is 4.7%, metrics that reveal how effectively management utilizes shareholder capital and total assets to generate returns, with the ROE significantly outpacing the ROA due to the leverage employed in the capital structure.

バリュエーション評価

The trailing P/E ratio is 20.02, while the forward P/E is 16.57, implying that the market expects earnings growth in the future that would justify a lower multiple relative to current earnings levels. The price-to-book ratio stands at 2.03, indicating that the company trades at a premium over its book value, which often reflects intangible assets, brand equity, and growth prospects not captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 4.04 and an EV/EBITDA of 35.19 suggest that investors are pricing the company based on its sales volume and cash-generating capability relative to enterprise value, rather than just accounting earnings. The stock has traded between a 52-week low of $8.71 and a 52-week high of $11.42; assuming the current trading price aligns with the forward P/E of 16.57 against the forward earnings, the valuation sits in the upper portion of its recent trading range, approaching the 52-week high of $11.42. With a beta of 0.33, the stock exhibits low volatility relative to the broader market, indicating that its price movements are generally less sensitive to overall market fluctuations compared to the average equity.

Growth & Income

Revenue growth year-over-year is 0.6%, whereas earnings growth year-over-year is 92.0%, indicating that earnings are growing significantly faster than revenue, which implies potential cost synergies, asset write-downs, or one-time gains impacting the bottom line more than the top line. As a dividend payer, the company offers a dividend yield of 1.9% with a payout ratio of 37.1%, a level that suggests the dividend is sustainable given the strong earnings growth and healthy free cash flow generation relative to the payout obligations. The disparity between modest revenue expansion and robust earnings expansion highlights a period of operational efficiency or structural change within the business model. Overall, the growth and income profile presents a company with stable, low-volatility characteristics and a growing earnings base that supports a consistent, albeit moderate, dividend distribution to shareholders.

同業他社比較

Haleon plc (HLN) は製薬 - 専門・ジェネリック業界で事業を展開しています。時価総額による最も近い同業他社との比較は以下の通りです:

企業名 ティッカー 時価総額 PER
Haleon plc HLN $40.92B 18.5
Takeda Pharmaceutical Company Limited TAK $50.14B 41.8
Teva Pharmaceutical Industries Limited TEVA $40.30B 25.8
Zoetis Inc. ZTS $33.63B 13.2

製薬 - 専門・ジェネリック業界の平均PERは47.5倍です。Haleon plcのPERは18.5です。

この分析はAIによって生成されたものであり、情報提供のみを目的としています。投資アドバイスではありません。データは遅延または不正確な場合があります。投資判断を行う前に、必ずご自身で調査を行い、資格を持つファイナンシャルアドバイザーにご相談ください。

Haleon plcについて

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

企業説明は英語で表示されています。

ウェブサイトを見る →

主要指標

時価総額
$40.92B
PER
18.48
52週高値
$11.42
52週安値
$8.71
平均出来高
8.46M
ベータ
0.25
配当利回り
2.09%

データはYahoo Financeよりyfinance経由で提供。毎日更新。

企業情報

取引所
NYSE
United Kingdom
従業員数
24,535